Unadjusted clinical outcomes by degree of HLA-A, -B, -C, -DRB1 match
| . | 8/8 . | 7/8 . | 6/8 . |
|---|---|---|---|
| No. patients | 1840 | 985 | 633 |
| Overall survival at 5 y | 37 (35-40) | 29 (26-32) | 22 (19-26) |
| Overall survival at 1 y | 52 (50-54) | 43 (40-46) | 33 (30-37) |
| Disease-free survival at 1 y | 47 (44-49) | 38 (35-42) | 29 (26-33) |
| Treatment-related mortality at 1 y | 36 (34-38) | 45 (42-49) | 55 (51-59) |
| Relapse at 1 y | 18 (16-19) | 16 (14-18) | 15 (13-18) |
| Chronic GVHD at 1 y | 44 (41-46) | 36 (33-39) | 32 (29-36) |
| Acute GVHD grade III-IV at 100 days | 28 (26-30) | 37 (34-40) | 44 (40-48) |
| Failure to engraft at 28 days | 10 (9-11) | 13 (10-15) | 17 (14-20) |
| . | 8/8 . | 7/8 . | 6/8 . |
|---|---|---|---|
| No. patients | 1840 | 985 | 633 |
| Overall survival at 5 y | 37 (35-40) | 29 (26-32) | 22 (19-26) |
| Overall survival at 1 y | 52 (50-54) | 43 (40-46) | 33 (30-37) |
| Disease-free survival at 1 y | 47 (44-49) | 38 (35-42) | 29 (26-33) |
| Treatment-related mortality at 1 y | 36 (34-38) | 45 (42-49) | 55 (51-59) |
| Relapse at 1 y | 18 (16-19) | 16 (14-18) | 15 (13-18) |
| Chronic GVHD at 1 y | 44 (41-46) | 36 (33-39) | 32 (29-36) |
| Acute GVHD grade III-IV at 100 days | 28 (26-30) | 37 (34-40) | 44 (40-48) |
| Failure to engraft at 28 days | 10 (9-11) | 13 (10-15) | 17 (14-20) |
Data are given as percent (95% CI).